{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:59:22Z","timestamp":1786481962788,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.08.021","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:48:16Z","timestamp":1473425296000},"page":"213-220.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies"],"prefix":"10.1016","volume":"15","author":[{"given":"Andrea","family":"Necchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Oualla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Boffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Busia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.08.021_bib1","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","article-title":"Testicular germ cell tumours","volume":"387","author":"Rajpert-De Meyts","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.08.021_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2015.07.021","article-title":"The changing landscape of intermediate- and poor-risk germ cell tumors: do we need to reclassify patients with metastatic germ cell tumors?","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Cancer Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","volume":"15","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on testicular cancer: 2015 update","volume":"68","author":"Albers","year":"2015","journal-title":"Eur Urol"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2016.08.021_bib5","doi-asserted-by":"crossref","first-page":"vi125","DOI":"10.1093\/annonc\/mdt304","article-title":"Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow up","volume":"24","author":"Oldenburg","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib6","unstructured":"National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Testicular Cancer. Version 2.2016. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf. Accessed: March 31,\u00a02016."},{"key":"10.1016\/j.clgc.2016.08.021_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.clgc.2016.08.021_bib8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.6004\/jnccn.2006.0088","article-title":"Review of late complications of treatment and late relapse in testicular cancer","volume":"4","author":"Efstathiou","year":"2006","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2016.08.021_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/bjc.1998.628","article-title":"Fatal bleomycin toxicity in the west of Scotland 1991-1995: a review of patients with germ cell tumors","volume":"78","author":"Simpson","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ucl.2015.05.002","article-title":"Long-term morbidity of testicular cancer treatment","volume":"42","author":"Fung","year":"2015","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.clgc.2016.08.021_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O'Sullivan","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/djk111","article-title":"Noncancer causes of death in survivors of testicular cancer","volume":"99","author":"Fossa","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.08.021_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urolonc.2014.11.012","article-title":"Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors","volume":"33","author":"Haugnes","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib14","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2012.43.4431","article-title":"Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up","volume":"30","author":"Haugnes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1995.24","article-title":"Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect","volume":"71","author":"Sleijfer","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib16","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clgc.2016.08.021_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1991.9.1.70","article-title":"A\u00a0randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study","volume":"9","author":"Wozniak","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","article-title":"Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol","volume":"9","author":"Nichols","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.1993.11.4.598","article-title":"Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study","volume":"11","author":"Bajorin","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.1993.11.7.1300","article-title":"The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group","volume":"11","author":"Levi","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib21","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/bjc.1995.254","article-title":"Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group","volume":"71","author":"de Wit","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.1995.13.2.470","article-title":"Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial","volume":"13","author":"Loehrer","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/oxfordjournals.annonc.a010493","article-title":"A\u00a0randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with \u2018good-risk\u2019 metastatic nonseminomatous germ cell tumors","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib24","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.1997.15.5.1844","volume":"15","author":"Horwich","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","article-title":"Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group","volume":"15","author":"de Wit","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1998.16.2.702","article-title":"Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience","volume":"16","author":"Saxman","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study","volume":"16","author":"Nichols","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib29","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.2001.19.6.1629","volume":"19","author":"de Wit","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(00)04165-9","article-title":"Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group","volume":"357","author":"Toner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.08.021_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"Daugaard","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib32","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/cncr.11271","article-title":"Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial","volume":"97","author":"Hinton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","article-title":"Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors","volume":"25","author":"Motzer","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.eururo.2006.10.035","article-title":"Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial","volume":"51","author":"Droz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.021_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2007.13.8461","volume":"26","author":"Culine","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2011.37.0171","article-title":"Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983","volume":"30","author":"de Wit","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib38","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2013.09.004","article-title":"A\u00a0risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study","volume":"65","author":"Fizazi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.021_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2014.06.034","article-title":"A\u00a0randomised phase 2 trial of intensive induction chemotherapy (CBOP\/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05\/014, ISRCTN 53643604)","volume":"67","author":"Huddart","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.08.021_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/annonc\/mdu485","article-title":"High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study","volume":"26","author":"Necchi","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2016.08.021_bib42","article-title":"A\u00a0retrospective analysis of patients with intermediate-risk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010","volume":"30","author":"Albany","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib43","doi-asserted-by":"crossref","first-page":"332e19","DOI":"10.1016\/j.urolonc.2015.04.008","article-title":"Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: implications for clinical practice, trial design, and molecular interrogation","volume":"33","author":"Raggi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clgc.2015.02.002","article-title":"Clinical outcomes of metastatic poor prognosis germ cell tumors: current perspective from a referral center","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.08.021_bib45","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/annonc\/mdw045","article-title":"Prognostic factors in patients with poor risk germ cell tumors: a retrospective analysis of the Indiana University experience from 1990-2014","volume":"27","author":"Adra","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib46","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1200\/JCO.2007.14.1606","article-title":"Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer","volume":"26","author":"de Haas","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.021_bib47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01213011-200506000-00005","article-title":"Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients","volume":"15","author":"Nuver","year":"2005","journal-title":"Pharmacogenet Genomics"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:46Z","timestamp":1761564406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316302555"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.021","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}